Novel insight into the pathobiology of abdominal aortic aneurysm and potential future treatment concepts

Prog Cardiovasc Dis. 2007 Nov-Dec;50(3):209-17. doi: 10.1016/j.pcad.2007.05.001.

Abstract

The patient with abdominal aortic aneurysm (AAA) commonly is a nondiabetic, white man with a history of smoking. Moreover, AAA represents a leading cause of death in elderly men in Western countries. The purpose of this manuscript is to review current evidence as to the pathobiology of AAA as well as potential future drug targets to prevent progression of AAA.

Publication types

  • Review

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Aorta / drug effects
  • Aorta / enzymology
  • Aorta / metabolism
  • Aorta / pathology*
  • Aortic Aneurysm, Abdominal / drug therapy
  • Aortic Aneurysm, Abdominal / etiology
  • Aortic Aneurysm, Abdominal / metabolism
  • Aortic Aneurysm, Abdominal / pathology*
  • Atherosclerosis / complications
  • Atherosclerosis / pathology
  • Cardiovascular Agents / pharmacology
  • Cardiovascular Agents / therapeutic use*
  • Extracellular Matrix Proteins / metabolism
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Inflammation / complications
  • Inflammation / pathology
  • MAP Kinase Kinase 4 / antagonists & inhibitors
  • MAP Kinase Kinase 4 / metabolism
  • Male
  • Oxidative Stress
  • Peptide Hydrolases / metabolism
  • Protease Inhibitors / therapeutic use
  • Risk Factors
  • Vitamins / therapeutic use

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Cardiovascular Agents
  • Extracellular Matrix Proteins
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Protease Inhibitors
  • Vitamins
  • MAP Kinase Kinase 4
  • Peptide Hydrolases